🚀 VC round data is live in beta, check it out!
Arvinas Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arvinas and similar public comparables like Astria Therapeutics, Alto Neuroscience, Allogene Therapeutics, BridgeBio Oncology and more.
Arvinas Overview
About Arvinas
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Founded
2013
HQ
Employees
246
Website
Sectors
Financials (LTM)
EV
$37M
Arvinas Financials
Arvinas reported last 12-month revenue of $216M and negative EBITDA of ($141M).
In the same LTM period, Arvinas generated $216M in gross profit, ($141M) in EBITDA losses, and had net loss of ($121M).
Revenue (LTM)
Arvinas P&L
In the most recent fiscal year, Arvinas reported revenue of $263M and EBITDA of ($113M).
Arvinas expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $216M | XXX | $263M | XXX | XXX | XXX |
| Gross Profit | $216M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($141M) | XXX | ($113M) | XXX | XXX | XXX |
| EBITDA Margin | (65%) | XXX | (43%) | XXX | XXX | XXX |
| EBIT Margin | (71%) | XXX | (45%) | XXX | XXX | XXX |
| Net Profit | ($121M) | XXX | ($81M) | XXX | XXX | XXX |
| Net Margin | (56%) | XXX | (31%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arvinas Stock Performance
Arvinas has current market cap of $713M, and enterprise value of $37M.
Market Cap Evolution
Arvinas' stock price is $11.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37M | $713M | -0.5% | XXX | XXX | XXX | $-1.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArvinas Valuation Multiples
Arvinas trades at 0.2x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Arvinas Financial Valuation Multiples
As of April 11, 2026, Arvinas has market cap of $713M and EV of $37M.
Equity research analysts estimate Arvinas' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arvinas has a P/E ratio of (5.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $713M | XXX | $713M | XXX | XXX | XXX |
| EV (current) | $37M | XXX | $37M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.2x | XXX | — | XXX | XXX | XXX |
| P/E | (5.9x) | XXX | (8.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arvinas Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arvinas Margins & Growth Rates
Arvinas' revenue in the last 12 month declined by (58%).
Arvinas' revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.5M for the same period.
Arvinas' rule of 40 is (296%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arvinas' rule of X is (392%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Arvinas Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (58%) | XXX | (65%) | XXX | XXX | XXX |
| EBITDA Margin | (65%) | XXX | (43%) | XXX | XXX | XXX |
| EBITDA Growth | 56% | XXX | 90% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (296%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (392%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 44% | XXX | 37% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 128% | XXX | 109% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 145% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arvinas Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Astria Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alto Neuroscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Allogene Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| SpyGlass Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arvinas M&A Activity
Arvinas acquired XXX companies to date.
Last acquisition by Arvinas was on XXXXXXXX, XXXXX. Arvinas acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arvinas
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArvinas Investment Activity
Arvinas invested in XXX companies to date.
Arvinas made its latest investment on XXXXXXXX, XXXXX. Arvinas invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arvinas
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arvinas
| When was Arvinas founded? | Arvinas was founded in 2013. |
| Where is Arvinas headquartered? | Arvinas is headquartered in United States. |
| How many employees does Arvinas have? | As of today, Arvinas has over 246 employees. |
| Who is the CEO of Arvinas? | Arvinas' CEO is Randy Teel. |
| Is Arvinas publicly listed? | Yes, Arvinas is a public company listed on Nasdaq. |
| What is the stock symbol of Arvinas? | Arvinas trades under ARVN ticker. |
| When did Arvinas go public? | Arvinas went public in 2018. |
| Who are competitors of Arvinas? | Arvinas main competitors are Astria Therapeutics, Alto Neuroscience, Allogene Therapeutics, BridgeBio Oncology. |
| What is the current market cap of Arvinas? | Arvinas' current market cap is $713M. |
| What is the current revenue of Arvinas? | Arvinas' last 12 months revenue is $216M. |
| What is the current revenue growth of Arvinas? | Arvinas revenue growth (NTM/LTM) is (58%). |
| What is the current EV/Revenue multiple of Arvinas? | Current revenue multiple of Arvinas is 0.2x. |
| Is Arvinas profitable? | No, Arvinas is not profitable. |
| What is the current EBITDA of Arvinas? | Arvinas has negative EBITDA and is not profitable. |
| What is Arvinas' EBITDA margin? | Arvinas' last 12 months EBITDA margin is (65%). |
| What is the current EV/EBITDA multiple of Arvinas? | Current EBITDA multiple of Arvinas is (0.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.